生物制药已成为全球增长最快的行业之一，也是中国高新技术发展的重点。在全球金融危机的阴影下，新兴国家医药市场却表现得风光独好，中国的生物制药市场也分外亮丽。康科于近年进入生物制药领域，不断延伸高端价值，持续参与投资开发新型生物药物制剂，目前自主品牌恩替卡韦片剂（乙肝病毒临床药物）原料药及成品已经研制完成。该项目前景稳定，成本优势明显，市场需求巨大，预计在带来良好社会效益的同时，也将有较高的投资回报。
　　Biopharmaceutical has become one of the fastest growing industries globally and the focus of China's high-tech development. In the shadow of the global financial crisis, the pharmaceutical market of emerging countries including China has performed well. Concorde has entered the sector in recent years,  participating in the development of new biopharmaceutical projects. At present, the raw material and finished products of Entecavir tablets (the latest drug for hepatitis B virus) have been developed. It is expected that the project will bring good social benefits and return on investment.